181 related articles for article (PubMed ID: 33634985)
1. CCL4-mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease.
Gong W; Yu J; Zheng T; Liu P; Zhao F; Liu J; Hong Z; Ren H; Gu G; Wang G; Wu X; Zhao Y; Ren J
Clin Transl Med; 2021 Feb; 11(2):e339. PubMed ID: 33634985
[TBL] [Abstract][Full Text] [Related]
2. Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases.
Biagioli M; Mencarelli A; Carino A; Cipriani S; Marchianò S; Fiorucci C; Donini A; Graziosi L; Baldelli F; Distrutti E; Costantino G; Fiorucci S
Inflamm Bowel Dis; 2017 Dec; 24(1):123-135. PubMed ID: 29272492
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis.
Kurniawan DW; Jajoriya AK; Dhawan G; Mishra D; Argemi J; Bataller R; Storm G; Mishra DP; Prakash J; Bansal R
J Control Release; 2018 Oct; 288():227-238. PubMed ID: 30219279
[TBL] [Abstract][Full Text] [Related]
4. SYK-CARD9 Signaling Axis Promotes Gut Fungi-Mediated Inflammasome Activation to Restrict Colitis and Colon Cancer.
Malik A; Sharma D; Malireddi RKS; Guy CS; Chang TC; Olsen SR; Neale G; Vogel P; Kanneganti TD
Immunity; 2018 Sep; 49(3):515-530.e5. PubMed ID: 30231985
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
[TBL] [Abstract][Full Text] [Related]
6. Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease.
Shrestha N; Xu Y; Prévost JRC; McCartney F; Brayden D; Frédérick R; Beloqui A; Préat V
Acta Biomater; 2022 Mar; 140():561-572. PubMed ID: 34923097
[TBL] [Abstract][Full Text] [Related]
7. Leaky gut model of the human intestinal mucosa for testing siRNA-based nanomedicine targeting JAK1.
Hartwig O; Loretz B; Nougarede A; Jary D; Sulpice E; Gidrol X; Navarro F; Lehr CM
J Control Release; 2022 May; 345():646-660. PubMed ID: 35339579
[TBL] [Abstract][Full Text] [Related]
8. Mincle/Syk Signalling Promotes Intestinal Mucosal Inflammation Through Induction of Macrophage Pyroptosis in Crohn's Disease.
Gong W; Zheng T; Guo K; Fang M; Xie H; Li W; Tang Q; Hong Z; Ren H; Gu G; Wang G; Wu X; Zhao Y; Ren J
J Crohns Colitis; 2020 Dec; 14(12):1734-1747. PubMed ID: 32333776
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibition of toll-like receptors-mediated JNK signaling pathway.
Lin YC; Huang DY; Chu CL; Lin WW
Mol Immunol; 2010 Apr; 47(7-8):1569-78. PubMed ID: 20138367
[TBL] [Abstract][Full Text] [Related]
10. Targeting uPA-uPAR interaction to improve intestinal epithelial barrier integrity in inflammatory bowel disease.
Cheng Y; Hall TR; Xu X; Yung I; Souza D; Zheng J; Schiele F; Hoffmann M; Mbow ML; Garnett JP; Li J
EBioMedicine; 2022 Jan; 75():103758. PubMed ID: 34933179
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of spleen tyrosine kinase (syk) suppresses renal fibrosis through anti-inflammatory effects and down regulation of the MAPK-p38 pathway.
Chen KH; Hsu HH; Yang HY; Tian YC; Ko YC; Yang CW; Hung CC
Int J Biochem Cell Biol; 2016 May; 74():135-44. PubMed ID: 26948651
[TBL] [Abstract][Full Text] [Related]
12. Spleen tyrosine kinase inhibition blocks airway constriction and protects from Th2-induced airway inflammation and remodeling.
Tabeling C; Herbert J; Hocke AC; Lamb DJ; Wollin SL; Erb KJ; Boiarina E; Movassagh H; Scheffel J; Doehn JM; Hippenstiel S; Maurer M; Gounni AS; Kuebler WM; Suttorp N; Witzenrath M
Allergy; 2017 Jul; 72(7):1061-1072. PubMed ID: 27906453
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle-based therapeutic delivery of prohibitin to the colonic epithelial cells ameliorates acute murine colitis.
Theiss AL; Laroui H; Obertone TS; Chowdhury I; Thompson WE; Merlin D; Sitaraman SV
Inflamm Bowel Dis; 2011 May; 17(5):1163-76. PubMed ID: 20872832
[TBL] [Abstract][Full Text] [Related]
14. Generation of a novel system for studying spleen tyrosine kinase function in macrophages and B cells.
Miller AL; Zhang C; Shokat KM; Lowell CA
J Immunol; 2009 Jan; 182(2):988-98. PubMed ID: 19124742
[TBL] [Abstract][Full Text] [Related]
15. The ubiquitous role of spleen tyrosine kinase (Syk) in gut diseases: From mucosal immunity to targeted therapy.
Gong W; Liu P; Zheng T; Wu X; Zhao Y; Ren J
Int Rev Immunol; 2022; 41(5):552-563. PubMed ID: 34355656
[TBL] [Abstract][Full Text] [Related]
16. Capsulated Cellular Nanosponges for the Treatment of Experimental Inflammatory Bowel Disease.
Duan Y; Zhang E; Fang RH; Gao W; Zhang L
ACS Nano; 2023 Aug; 17(16):15893-15904. PubMed ID: 37565604
[TBL] [Abstract][Full Text] [Related]
17. TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent Models.
Hayashi H; Kaneko R; Demizu S; Akasaka D; Tayama M; Harada T; Irie H; Ogino Y; Fujino N; Sasaki E
J Pharmacol Exp Ther; 2018 Jul; 366(1):84-95. PubMed ID: 29728446
[TBL] [Abstract][Full Text] [Related]
18. Bioactives and metabolites of Tetrastigma hemsleyanum root extract alleviate DSS-induced ulcerative colitis by targeting the SYK protein in the B cell receptor signaling pathway.
Feng Z; Ye W; Feng L
J Ethnopharmacol; 2024 Mar; 322():117563. PubMed ID: 38104876
[TBL] [Abstract][Full Text] [Related]
19. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression.
Joshi S; Liu KX; Zulcic M; Singh AR; Skola D; Glass CK; Sanders PD; Sharabi AB; Pham TV; Tamayo P; Shiang D; Dinh HQ; Hedrick CC; Morales GA; Garlich JR; Durden DL
Mol Cancer Ther; 2020 Mar; 19(3):755-764. PubMed ID: 31974273
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Benefits of Spleen Tyrosine Kinase Inhibitor Administration on Binge Drinking-Induced Alcoholic Liver Injury, Steatosis, and Inflammation in Mice.
Bukong TN; Iracheta-Vellve A; Gyongyosi B; Ambade A; Catalano D; Kodys K; Szabo G
Alcohol Clin Exp Res; 2016 Jul; 40(7):1524-30. PubMed ID: 27177528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
